Laboratoire X.O

# Laboratoire X.O Laboratoire X.O, also known as LXO, is a dynamic pharmaceutical entity that has been **acting for health** since its inception in 2015. With a commitment to ensuring access, availability, and quality of essential medicines, LXO stands at the forefront of the healthcare industry. ## Core Values and Commitments - **Quality, Ethics, and Transparency**: At the heart of LXO's operations lies a steadfast commitment to these principles, ensuring that every action and decision upholds the highest standards. - **Innovation and Agility**: LXO prides itself on its ability to adapt and respond to the ever-evolving needs of the healthcare sector, driving progress and innovation. ## Therapeutic Areas LXO has made significant strides in various therapeutic areas, including: - Cardiology - Central Nervous System - Internal Medicine ## Key Figures - **20** add-ons since 2015 - Over **€90M** in turnover - **18** brands and **26** products - Presence in over **80+** countries - A dedicated team of **40+** collaborators across France, Ireland, and the US ## Milestones and Achievements - **Acquisition of Nimotop®**: Marking a significant milestone, LXO acquired the prescription drug Nimotop® from Bayer, expanding its portfolio and international footprint. - **Expansion**: To accommodate its growth, LXO moved to new premises, fostering an environment conducive to creativity and collaboration. ## Global Presence With headquarters in Île-de-France, LXO has established a robust presence across the globe, including strategic expansions in the US and the acquisition of Noden Pharma DAC in Dublin, enhancing its European market expertise. ## Future Outlook LXO continues to pursue opportunities for growth, both organically and through external avenues, with a clear focus on delivering life-saving drugs and maintaining its reputation as a leader in the pharmaceutical industry.